TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Fulfill diagnostic criteria for AERD (described below), and be a candidate for aspirin desensitization chronic asthma - frequently moderate-severe or severe patients will have history compatible with variable airflow obstruction. chronic rhinosinusitis - usually requiring previous sinus surgery procedure(s). sinusitis will have been confirmed by imaging studies presently and/or in the past.~history of adverse reaction to aspirin and/or aspirin-like drugs (e.g., ibuprofen, naproxen, etc.) compatible with AERD.~• Candidate for Xolair \[Omalizumab\] Moderate-severe persistent asthma IgE = 30-700 IU/ml IgE mediated (allergic) potential to inhalant allergen(s) by cutaneous or in vitro testing.~Exclusion Criteria:~* Women of childbearing potential not using appropriate contraception method(s)~* Women currently breastfeeding~* Women who desire to become pregnant during the time of participation in this study~* Men who desire to get someone pregnant during participation in this study~* Known sensitivity to Xolair \[Omalizumab\].~* IgE level \< 30 IU/ml, or \> 700 IU/ml.~* No evidence of atopy by immediate hypersensitivity skin testing~* Use of any other investigational agent in the last 30 days~* Age \< 18 years.~* Current tobacco habituation.~* Presence of emphysema~* Ethanolism or drug abuse within last 12 months.~* Presence of significant medical condition including malignancy, neurologic, kidney, gastrointestinal, liver or cardiovascular disease~* extensive travel commitments during the study that would interfere with study measurements or clinic visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo
- Omalizumab Group (Type: ACTIVE_COMPARATOR): Subjects randomized to omalizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders presenting with chronic anal fissure of more than 6 weeks in duration~* Ageing between 18 and 65 years old.~Exclusion Criteria:~* Pregnant patients.~* Patients with recurrent anal fissure after previous sphincterotomy.~* Patients with coexisting anorectal diseases or inflammatory bowel diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Minoxidil (Type: ACTIVE_COMPARATOR): Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
- Glyceryl trinitrate (Type: ACTIVE_COMPARATOR): Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participation in either of the CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] clinical studies in which the subject completed the trial at Week 26. Subjects may have received active or placebo or both treatments in the prior study~* Subjects must be able to understand the information provided to them and give written informed consent~Exclusion Criteria:~* Any exclusion criterion that would have prevented the subject's participation in the qualifying pivotal study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\], although the criterion that excludes previous participation in a clinical trial of Certolizumab Pegol does not apply. In addition there are no limits on the Clinical Disease Activity Index (CDAI) score at entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol (Type: EXPERIMENTAL): 400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a healthy male or female, 12-14 months of age at the time of first vaccination, who received at least one dose of pneumococcal conjugate vaccine during study 105553 and with written informed consent obtained from the parent/guardian of the subject.~Exclusion Criteria:~* use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the vaccination, or planned use during the entire study period (active phase and safety follow-up).~* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before the first dose of vaccine(s) and ending 42-56 days after the last dose of vaccine(s).~* Administration of any additional pneumococcal vaccine since end of study 105553.~* Previous vaccination against measles, mumps, rubella and/or varicella. History of, or intercurrent measles, mumps, rubella and/or varicella/zoster diseases.~* Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to study start.~* Immunosuppressive or immunodeficient condition.~* A history of seizures or neurological disease.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 14 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 9 to 23 months at the time of receipt of the first dose of Menactra vaccine during the study period.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: None): Participants must have received Menactra Vaccine according to routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who signed a personal consent to participate in the study,~* Patients with a typical clinical picture of moderately-severe to severe plaque psoriasis (PASI SCORE ≥10) and~* DMT2 diagnosed at least 6 months before inclusion in the study,~* Patients who were not treated with immunosuppressive therapy.~Exclusion Criteria:~* Other forms of psoriasis,~* Other chronic, inflammatory diseases (data obtained by reviewing the medical history),~* Drugs that can cause the appearance of psoriasis (lithium, systemic antimalarials, systemic corticosteroids) - for the past 3 months,~* Systemic therapy of vulgaris psoriasis 3 months before inclusion in the study,~* Patients on therapy with other GLP-1 RAs except semaglutide (liraglutide, dulaglutide, lixisenatide), SGLT-2 inhibitors (empagliflozin and dapagliflozin) and NSAIDs, photo UVB therapy,~* Patients who did not personally sign consent to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- semaglutide (Type: EXPERIMENTAL): The initial dose of the medicine is 0.25 mg once a week, for the duration of 4 weeks. Then the dose is increased to 0.5 mg per week, for the duration of 4 weeks. After at least 4 weeks, the dose can be increased from 0.5 mg to 1 mg per 4 week. Totally 12 weeks
- controled group (Type: NO_INTERVENTION): Patients with DMT2 and psoriasis, who are already on metformin therapy in the maximally tolerated dose and other oral antidiabetics, except on therapy with GLP-1 RA and SGLT-2 inhibitors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morbidity in Newly Diagnosed type2 Diabetes in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged from 40 to 70 years~* Newly diagnosed type 2 diabetes~* Never treated for diabetes~Exclusion Criteria:~* Gestational diabetes

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Complications,no specific treatment (Type: None): After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of physician-diagnosed ragweed-induced allergic rhinoconjunctivitis of 2 years duration or more, with or without asthma~* Must have a positive skin prick test response to Ambrosia artemisiifolia~* Must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value~* Clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor~* Females of child-bearing potential must agree to use medically accepted methods of contraception~Exclusion Criteria:~* Unstable asthma or has experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids in previous 3 months~* Received an immunosuppressive treatment within 3 months~* History of anaphylaxis with cardio-respiratory symptoms.~* History of chronic urticaria or angioedema~* Current severe atopic dermatitis~* Female subject who is breastfeeding, pregnant, or intending to become pregnant~* Has received maintenance doses of immunotherapy with ragweed extract for ≥1 month within the last 5 years~* History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine~* Unable to or will not comply with the use of self-injectable epinephrine~* Participating in any other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCH 39641 12 Amb a 1-U (Type: EXPERIMENTAL): 12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet, sublingual, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men~* Aged 18-50 years~* With normal clinical chemistry, serum levels of testosterone, PSA, gonadotropins within normal limits, and sperm concentration greater than 20 million/mL~* Subject or his partner willing to use a recognized effective method of contraception~Exclusion Criteria:~* Men not living in area of clinics~* Clinically significant abnormal findings at screening~* Elevated PSA greater than 4~* Partners who are pregnant~* Abnormal laboratory values, liver or kidney dysfunction~* Sperm counts below 20 million/mL.~* Use of androgens or body building substances within 6 months of enrollment,~* Blood pressure greater than 140/90, history of hypertension, including hypertension controlled with treatment~* History of primary testicular disease or disorder of the hypothalamic-pituitary axis~* Hypersensitivity of progestins~* History of venous thromboembolism~* Benign or malignant liver tumors~* Active liver disease, history of reproductive dysfunction including vasectomy or infertility~* History of active or chronic cardiac, renal, hepatic or prostatic disease~* Diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight)~* Known or suspected alcoholism or drug abuse~* Known dermatitis or severe skin disorder~Men desiring fertility within 6 months or participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 100 mg Testosterone gel daily for 3 weeks
- 2 (Type: ACTIVE_COMPARATOR): 2 mg Nestorone gel daily for 3 weeks
- 3 (Type: ACTIVE_COMPARATOR): 4 mg Nestorone gel daily for 3 weeks
- 4 (Type: ACTIVE_COMPARATOR): 100 mg Testosterone gel + 2 mg Nestorone gel
- 5 (Type: ACTIVE_COMPARATOR): 100 mg Testosterone gel + 4 mg Nestorone gel
- 6 (Type: ACTIVE_COMPARATOR): 100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
- 7 (Type: ACTIVE_COMPARATOR): 100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Platelet Rich Plasma on Endometrium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women in whom cycle was cancelled due to an endometrial thickness \<7 mm when progesterone start was planned in patients undergoing frozen embryo transfer with hormone replacement therapy~* Women with a history of Asherman syndrome, but no obvious intrauterine adhesion in the last hysteroscopic procedure;~* Women who have at least 2 frozen good-quality embryos.~Exclusion Criteria:~* Women with any other known cause of implantation failure, such as poor embryo quality, or congenital uterine anomalies, endometrial polyp or fibroid,~* Previous diagnosis of any malignancy,~* Anticoagulant use for which plasma infusion is contraindicated,

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Endometrial PRP (Type: EXPERIMENTAL): Patients in whom endometrial PRP was performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>/=18 years of age~* HBeAg positive chronic hepatitis B~* Compensated liver disease~Exclusion Criteria:~* Patients who had previously received treatment of drugs with activity against HBV within 6 months prior to study start~* Antiviral, anti-neoplastic or immunomodulatory treatment~* Co-infection with active hepatitis A, hepatitis C, hepatitis D, or HIV~* Evidence of decompensated liver disease~* Chronic liver disease other than viral hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis B treatment naive~* Compensated liver disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1 (Type: ACTIVE_COMPARATOR): None
- A2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women and men with RA, AS and other inflammatory forms of arthritis, aged 35-80 years.~2. Cholesterol plaques demonstrated in carotid artery by ultrasound.~3. Informed consent.~Exclusion Criteria:~1. Concomitant statin treatment~2. Arterial fibrillation or others with chronic irregular heart rhythm (because of CT).~3. Contraindication to statin treatment.~   * Hypersensitivity to statins~  * Liver disease with ASAT/ALAT ≥ twice the upper normal limit~  * Previous statin-induced myopathy or severe hypersensitivity reactions to other statins~  * Raised creatinine (because of contrast medium)~  * Pregnancy or breast feeding~  * Fertile women who do not use contraceptives~  * Cyclosporine treatment~  * Treatment with medicinal products that have a known interaction with Rosuvastatin~  * Uncontrolled hypothyroidism defined as TSH \> 1.5 times ULN at the first visit (because of the connection between myopathy and hypothyroidism with statin treatment)~  * Creatinine clearance \< 30 ml/min and \<60 ml/min with a Rosuvastatin dose of 40 mg per day~4. Secondary hyperlipidemia~   * Primary hyperthyroidism~  * Nephrotic syndrome, creatinine \> 2 mg/dl~  * Uncontrolled diabetes mellitus (HbA1C \> 10 %)~  * Plasma Triglycerides \> 6.8 mmol/l~5. Other diseases or treatment that reduces the safety, or treatment with Rosuvastatin which would interfere with the end points of the study~   * Heart failure: NYHA class III B/IV~  * Haemodynamically significant valve defects~  * Established statin treatment~  * Gastrointestinal disease/treatment that can give malabsorption of Rosuvastatin~  * Cancer~  * Severe psychiatric disease~  * Life-threatening ventricular arrhythmias~  * Other medication that increases the risk of rhabdomyolysis~  * Known abuse of alcohol~  * Participation in other studies

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin intervention (Type: EXPERIMENTAL): Patients \> 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient \<70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Passive Mobilization and Vascular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bedridden~Exclusion Criteria:~* Neurodegenerative disease (i.e.Parkinson's disease, Alzheimer's disease)~* Heart failure~* Organ transplantation~* Liver failure~* Kidney failure~* Hemorrhage~* Neuromuscular diseases

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 110 Years
- Healthy Volunteers: t

Study Arms:
- Passive mobilization - PM (Type: EXPERIMENTAL): Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
- Control group - ctrl (Type: NO_INTERVENTION): Participants will receive ther standard therapies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete